跳至主要内容
临床试验/NCT00503503
NCT00503503已完成不适用

Safety and Efficacy From Large Scale All Cases Surveillance for Etanercept in Japan

Wyeth is now a wholly owned subsidiary of Pfizer0 个研究点开始时间: 2005年3月最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
发起方

研究概览

简要总结

The objective of this surveillance is to determine the following items in all patients receiving Enbrel for a certain period after marketing: 1) unlabeled adverse events, 2) onset (frequency, severity and other details) of adverse events, 3) factors considered to affect the safety, and 4) the efficacy of Enbrel. Moreover, the onset (frequency, severity and other details) of the followings will be key issues of this surveillance:Infection (tuberculosis, opportunistic infection, etc.), autoimmune diseases, cardiac failure, malignant tumor, interstitial pneumonia, demyelinating disorders, pancytopenia, aplastic anemia and application site reactions.

研究设计

研究类型
Observational
时间视角
Prospective

入排标准

年龄范围
11 Years 至 90 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究者

发起方
Wyeth is now a wholly owned subsidiary of Pfizer
申办方类型
Industry

相似试验